Skip to content

Clinical trials

Phase 2 Neurocognitive Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurocognitive Disorders Phase: Phase 2 Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20111
20151
20173
20185
20191
20201
20212
20221
20232
20253
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed12
Recruiting4
Terminated3
Unknown status2
Not yet recruiting1
Suspended1
Enrolling by invitation1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alkahest, Inc.3
Inmune Bio, Inc.2
MapLight Therapeutics2
Avraham Pharmaceuticals Ltd1
Biomed Industries, Inc.1
EIP Pharma Inc1
Eastern Virginia Medical School1
Eli Lilly and Company1
Genentech, Inc.1
Géraldine Martens1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurocognitive Disorders25
Brain Diseases14
Central Nervous System Diseases13
Nervous System Diseases13
Neurodegenerative Diseases13
Alzheimer Disease12
Dementia12
Mental Disorders12
Cognitive Dysfunction8
Tauopathies6

Trials

Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.